Targeting proteins with metal complexes.

Unique properties of metal complexes, such as structural diversity, adjustable ligand exchange kinetics, fine-tuned redox activities, and distinct spectroscopic signatures, make them exciting scaffolds not only for binding to nucleic acids but increasingly also to proteins as non-traditional targets. This feature article discusses recent trends in this field. These include the use of chemically inert metal complexes as structural scaffolds for the design of enzyme inhibitors, new strategies for inducing selective coordination chemistry at the protein binding site, recent advances in the development of catalytic enzyme inhibitors, and the design of metal complexes that can inject electrons or holes into redox enzymes. A common theme in many of the discussed examples is that binding selectivity is at least in part achieved through weak interactions between the ligand sphere and the protein binding site. These examples hint to an exciting future in which "organic-like" molecular recognition principles are combined with properties that are unique to metals and thus promise to yield compounds with novel and unprecedented properties.

[1]  S. Knapp,et al.  Extremely Tight Binding of a Ruthenium Complex to Glycogen Synthase Kinase 3 , 2008, Chembiochem : a European journal of chemical biology.

[2]  Ronen Marmorstein,et al.  Targeting large kinase active site with rigid, bulky octahedral ruthenium complexes. , 2008, Journal of the American Chemical Society.

[3]  H. Gray,et al.  Enantiomer-specific binding of ruthenium(II) molecular wires by the amine oxidase of Arthrobacter globiformis. , 2008, Journal of the American Chemical Society.

[4]  R. Webster,et al.  Similar biological activities of two isostructural ruthenium and osmium complexes. , 2008, Chemistry.

[5]  M. Herlyn,et al.  Structure-based design of an organoruthenium phosphatidyl-inositol-3-kinase inhibitor reveals a switch governing lipid kinase potency and selectivity. , 2008, ACS chemical biology.

[6]  D. Rehder The trigonal-bipyramidal NO4 ligand set in biologically relevant vanadium compounds and their inorganic models. , 2008, Journal of inorganic biochemistry.

[7]  J. Suh,et al.  Metal complexes as artificial proteases: toward catalytic drugs. , 2008, Current opinion in chemical biology.

[8]  Seann P. Mulcahy,et al.  Solid-phase synthesis of tris-heteroleptic ruthenium(II) complexes and application to acetylcholinesterase inhibition. , 2008, Inorganic chemistry.

[9]  J. Cowan,et al.  Catalytic inactivation of human carbonic anhydrase I by a metallopeptide-sulfonamide conjugate is mediated by oxidation of active site residues. , 2008, Journal of the American Chemical Society.

[10]  H. Gray,et al.  Probing inducible nitric oxide synthase with a pterin-ruthenium(II) sensitizer wire. , 2008, Angewandte Chemie.

[11]  T. Kodadek,et al.  A general system for evaluating the efficiency of chromophore-assisted light inactivation (CALI) of proteins reveals Ru(II) tris-bipyridyl as an unusually efficient "warhead". , 2008, Molecular bioSystems.

[12]  S. Fricker Metal based drugs: from serendipity to design. , 2007, Dalton transactions.

[13]  T. Hambley Developing new metal-based therapeutics: challenges and opportunities. , 2007, Dalton transactions.

[14]  Junghun Suh,et al.  Cleavage Agents for Soluble Oligomers of Amyloid β Peptides , 2007 .

[15]  P. Sadler,et al.  Using coordination chemistry to design new medicines , 2007 .

[16]  Eric Meggers,et al.  Exploring biologically relevant chemical space with metal complexes. , 2007, Current opinion in chemical biology.

[17]  R. Webster,et al.  Ruthenium half-sandwich complexes as protein kinase inhibitors: derivatization of the pyridocarbazole pharmacophore ligand. , 2007, Organic & biomolecular chemistry.

[18]  Seann P. Mulcahy,et al.  Exploring Chemical Space with Organometallics: Ruthenium Complexes as Protein Kinase Inhibitors , 2007 .

[19]  Eric Meggers,et al.  Platinum complex as a nanomolar protein kinase inhibitor. , 2007, Inorganic chemistry.

[20]  B. Brooks,et al.  Engineering Metal Complexes of Chiral Pentaazacrowns as Privileged Reverse‐turn Scaffolds , 2007, Chemical biology & drug design.

[21]  Simon Parsons,et al.  Configurations of nickel-cyclam antiviral complexes and protein recognition. , 2007, Chemistry.

[22]  K. Flaherty,et al.  An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells. , 2007, Cancer research.

[23]  E. Lam,et al.  A small molecule inhibitor for phosphatase and tensin homologue deleted on chromosome 10 (PTEN). , 2006, ACS chemical biology.

[24]  H. Bregman,et al.  Ruthenium half-sandwich complexes as protein kinase inhibitors: an N-succinimidyl ester for rapid derivatizations of the cyclopentadienyl moiety. , 2006, Organic letters.

[25]  G. E. Atilla‐Gokcumen,et al.  Organometallic Compounds with Biological Activity: A Very Selective and Highly Potent Cellular Inhibitor for Glycogen Synthase Kinase 3 , 2006, Chembiochem : a European journal of chemical biology.

[26]  J. Cowan,et al.  Metallopeptide-promoted inactivation of angiotensin-converting enzyme and endothelin-converting enzyme 1: toward dual-action therapeutics , 2006, JBIC Journal of Biological Inorganic Chemistry.

[27]  S. Fricker,et al.  Rhenium inhibitors of cathepsin B (ReO(SYS)X (where Y = S, py; X = Cl, Br, SPhOMe-p)): Synthesis and mechanism of inhibition. , 2006, Journal of medicinal chemistry.

[28]  N. Farrell,et al.  Targeting retroviral Zn finger-DNA interactions: a small-molecule approach using the electrophilic nature of trans-platinum-nucleobase compounds. , 2006, Chemistry & biology.

[29]  Garland R. Marshall,et al.  Development of small molecules designed to modulate protein–protein interactions , 2006, J. Comput. Aided Mol. Des..

[30]  P. Dyson,et al.  Metal-based antitumour drugs in the post genomic era. , 2006, Dalton transactions.

[31]  C. Che,et al.  A mixed-valent ruthenium-oxo oxalato cluster Na7[Ru4(mu3-O)4(C2O4)6] with potent anti-HIV activities. , 2006, Journal of the American Chemical Society.

[32]  K. Fritz-Wolf,et al.  Undressing of phosphine gold(I) complexes as irreversible inhibitors of human disulfide reductases. , 2006, Angewandte Chemie.

[33]  D. Christianson,et al.  Ultrahigh resolution crystal structures of human carbonic anhydrases I and II complexed with "two-prong" inhibitors reveal the molecular basis of high affinity. , 2006, Journal of the American Chemical Society.

[34]  S. Knapp,et al.  Ruthenium half-sandwich complexes bound to protein kinase Pim-1. , 2006, Angewandte Chemie.

[35]  N. Metzler‐Nolte,et al.  New principles in medicinal organometallic chemistry. , 2006, Angewandte Chemie.

[36]  Eric Meggers,et al.  Rapid access to unexplored chemical space by ligand scanning around a ruthenium center: discovery of potent and selective protein kinase inhibitors. , 2006, Journal of the American Chemical Society.

[37]  J. Cowan,et al.  Inactivation of human angiotensin converting enzyme by copper peptide complexes containing ATCUN motifs. , 2005, Chemical communications.

[38]  H. Gray,et al.  Picosecond photoreduction of inducible nitric oxide synthase by rhenium(I)-diimine wires. , 2005, Journal of the American Chemical Society.

[39]  H. Gray,et al.  Reversible inhibition of copper amine oxidase activity by channel-blocking ruthenium(II) and rhenium(I) molecular wires. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[40]  Melissa L. Golden,et al.  Thiolate-bridged heterodinuclear platinum-zinc chelates as models for ternary platinum-DNA-protein complexes and zinc ejection from zinc fingers. Evidence from studies using ESI-mass spectrometry. , 2005, Chemical communications.

[41]  S. Mallik,et al.  Inhibition of matrix metalloproteinase-9 by "multi-prong" surface binding groups. , 2005, Chemical communications.

[42]  J. Suh,et al.  Angiotensin-cleaving catalysts: conversion of N-terminal aspartate to pyruvate through oxidative decarboxylation catalyzed by Co(III)cyclen , 2005, JBIC Journal of Biological Inorganic Chemistry.

[43]  Douglas S. Williams,et al.  Switching on a signaling pathway with an organoruthenium complex. , 2005, Angewandte Chemie.

[44]  A. Vessières,et al.  Selective estrogen receptor modulators in the ruthenocene series. Synthesis and biological behavior. , 2005, Journal of medicinal chemistry.

[45]  Simon Parsons,et al.  Protein recognition of macrocycles: binding of anti-HIV metallocyclams to lysozyme. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[46]  Hwangseo Park,et al.  Peptide-cleaving catalyst selective for peptide deformylase. , 2005, Journal of the American Chemical Society.

[47]  R. Gust,et al.  Antitumor-active cobalt-alkyne complexes derived from acetylsalicylic acid: studies on the mode of drug action. , 2005, Journal of medicinal chemistry.

[48]  A. Vessières,et al.  Ferrocene-mediated proton-coupled electron transfer in a series of ferrocifen-type breast-cancer drug candidates. , 2005, Angewandte Chemie.

[49]  H. Sekizaki,et al.  Amidino-containing Schiff base copper(II) and iron(III) chelates as a thrombin inhibitor. , 2005, Chemical & pharmaceutical bulletin.

[50]  W. Hol,et al.  The power of vanadate in crystallographic investigations of phosphoryl transfer enzymes , 2004, FEBS letters.

[51]  Douglas S. Williams,et al.  An organometallic inhibitor for glycogen synthase kinase 3. , 2004, Journal of the American Chemical Society.

[52]  G. Leclercq,et al.  The first organometallic selective estrogen receptor modulators (SERMs) and their relevance to breast cancer. , 2004, Current medicinal chemistry.

[53]  Michael S. Cohen,et al.  Electron-transfer chemistry of Ru-linker-(heme)-modified myoglobin: rapid intraprotein reduction of a photogenerated porphyrin cation radical. , 2004, Inorganic chemistry.

[54]  E. Meggers,et al.  Ruthenium complexes as protein kinase inhibitors. , 2004, Organic letters.

[55]  P. Sadler,et al.  Anti-viral cyclam macrocycles : rapid zinc uptake at physiological pH. , 2004, Chemical communications.

[56]  H. Sakurai,et al.  Synthesis and insulinomimetic activities of novel mono- and tetranuclear oxovanadium(IV) complexes with 3-hydroxypyridine-2-carboxylic acid. , 2004, Journal of inorganic biochemistry.

[57]  T. Kodadek,et al.  Using oxidative crosslinking and proximity labeling to quantitatively characterize protein-protein and protein-Peptide complexes. , 2003, Chemistry & biology.

[58]  P. Sadler,et al.  Selective recognition of configurational substates of zinc cyclam by carboxylates: implications for the design and mechanism of action of anti-HIV agents. , 2003, Chemistry.

[59]  H. Gray,et al.  Nanosecond photoreduction of cytochrome p450cam by channel-specific Ru-diimine electron tunneling wires. , 2003, Journal of the American Chemical Society.

[60]  Nohad Gresh,et al.  Modeling of Copper(II) Complexes with the SIBFA Polarizable Molecular Mechanics Procedure. Application to a New Class of HIV-1 Protease Inhibitors , 2003 .

[61]  C. Orvig,et al.  Boon and Bane of Metal Ions in Medicine , 2003, Science.

[62]  Kasper P. Jensen,et al.  Metal ion enhanced binding of AMD3100 to Asp262 in the CXCR4 receptor. , 2003, Biochemistry.

[63]  Zoran Radić,et al.  Structural insights into ligand interactions at the acetylcholinesterase peripheral anionic site , 2003, The EMBO journal.

[64]  S. Son,et al.  Protein-cleaving catalyst selective for protein substrate. , 2002, Organic letters.

[65]  Chris M. W. Ho,et al.  Metal complexes of chiral pentaazacrowns as conformational templates for β-turn recognition , 2002, J. Comput. Aided Mol. Des..

[66]  Xiangyang Liang,et al.  Structure and dynamics of metallomacrocycles: recognition of zinc xylyl-bicyclam by an HIV coreceptor. , 2002, Journal of the American Chemical Society.

[67]  A. Mouithys-Mickalad,et al.  Metal-organic compounds: a new approach for drug discovery. N1-(4-methyl-2-pyridyl)-2,3,6-trimethoxybenzamide copper(II) complex as an inhibitor of human immunodeficiency virus 1 protease. , 2002, Biochemical pharmacology.

[68]  H. Gray,et al.  Sensitizer-linked substrates and ligands: ruthenium probes of cytochrome P450 structure and mechanism. , 2002, Methods in enzymology.

[69]  A. Dunn,et al.  Probing the open state of cytochrome P450cam with ruthenium-linker substrates , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[70]  B C Roy,et al.  Surface recognition of a protein using designed transition metal complexes. , 2001, Journal of the American Chemical Society.

[71]  A. Tracey,et al.  Vanadium(V) complexes in enzyme systems: aqueous chemistry, inhibition and molecular modeling in inhibitor design. , 2001, Journal of inorganic biochemistry.

[72]  M. James,et al.  X-ray crystallographic analyses of complexes between bovine beta-trypsin and Schiff base copper(II) or iron(III) chelates. , 2001, Journal of molecular biology.

[73]  T. Kodadek,et al.  Scope, limitations and mechanistic aspects of the photo-induced cross-linking of proteins by water-soluble metal complexes. , 2000, Chemistry & biology.

[74]  Zou,et al.  First Crystal Structure of a Medicinally Relevant Gold Protein Complex: Unexpected Binding of , 2000, Angewandte Chemie.

[75]  H. Gray,et al.  Optical detection of cytochrome P450 by sensitizer-linked substrates. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[76]  Tomohiko Maehama,et al.  Crystal Structure of the PTEN Tumor Suppressor Implications for Its Phosphoinositide Phosphatase Activity and Membrane Association , 1999, Cell.

[77]  C. Shaw Gold-Based Therapeutic Agents , 1999 .

[78]  T. Meade,et al.  Metal complexes as enzyme inhibitors. , 1999, Chemical reviews.

[79]  D. Riley Functional mimics of superoxide dismutase enzymes as therapeutic agents. , 1999, Chemical reviews.

[80]  P. Sadler,et al.  Metals in Medicine. , 1999, Angewandte Chemie.

[81]  T. Kodadek,et al.  Chemistry for the analysis of protein-protein interactions: rapid and efficient cross-linking triggered by long wavelength light. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[82]  H. Gray,et al.  Substrates for Rapid Delivery of Electrons and Holes to Buried Active Sites in Proteins , 1999 .

[83]  F. Durant,et al.  De novo drug design of a new copper chelate molecule acting as HIV-1 protease inhibitor , 1998 .

[84]  M. Simon,et al.  Selective Inhibition of Human α-Thrombin by Cobalt(III) Schiff Base Complexes , 1998 .

[85]  T. Meade,et al.  A cobalt complex that selectively disrupts the structure and function of zinc fingers. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[86]  R. Schinazi,et al.  Polyoxometalates in Medicine. , 1998, Chemical reviews.

[87]  A. Walts,et al.  Protease activity of 1,10-phenanthroline-copper(I). Targeted scission of the catalytic site of carbonic anhydrase. , 1998, Biochemistry.

[88]  M. Gresser,et al.  Mechanism of Inhibition of Protein-tyrosine Phosphatases by Vanadate and Pervanadate* , 1997, The Journal of Biological Chemistry.

[89]  M. Zhou,et al.  Crystal structure of bovine low molecular weight phosphotyrosyl phosphatase complexed with the transition state analog vanadate. , 1997, Biochemistry.

[90]  D G Jay,et al.  Chromophore-assisted laser inactivation (CALI): probing protein function in situ with a high degree of spatial and temporal resolution. , 1996, Trends in cell biology.

[91]  H. Matter,et al.  Structures, Dynamics, and Biological Activities of 15 Cyclic Hexapeptide Analogs of the .alpha.-Amylase Inhibitor Tendamistat (HOE 467) in Solution , 1995 .

[92]  M. Lipton,et al.  Cyclic hexapeptides and chimeric peptides as mimics of tendamistat , 1994 .

[93]  Peter G. Schultz,et al.  A new strategy for selective protein cleavage , 1990 .

[94]  Alanna Schepartz,et al.  Site-Specific Cleavage of the Protein Calmodulin Using a Trifluoperazine-Based Affinity Reagent , 1990 .

[95]  F. P. Dwyer,et al.  The biological actions of 1,10-phenanthroline and 2,2'-bipyridine hydrochlorides, quaternary salts and metal chelates and related compounds. 1. Bacteriostatic action on selected gram-positive, gram-negative and acid-fast bacteria. , 1969, The Australian journal of experimental biology and medical science.

[96]  E. Mayhew,et al.  Inhibition of Landschütz Ascites Tumour Growth by Metal Chelates Derived from 3,4,7,8-Tetramethyl-1,10-phenanthroline , 1965, British Journal of Cancer.

[97]  F. P. Dwyer,et al.  Effect of Inorganic Complex Ions on Transmission at a Neuromuscular Junction , 1957, Nature.

[98]  F. P. Dwyer,et al.  The Metabolic Fate of Tris-1,10-Phenanthroline 106Ruthenium (II) Perchlorate, a Compound With Anticholinesterase and Curare-Like Activity , 1957 .

[99]  F. P. Dwyer,et al.  Biological Activity of Complex Ions , 1952, Nature.